Wrap Text
Unaudited interim results for the six months ended 31 December 2021 and cash dividend declaration
Adcock Ingram Holdings Limited
(Incorporated in the Republic of South Africa)
(Registration number 2007/016236/06)
Share code: AIP ISIN: ZAE000123436
("Adcock Ingram" or "the Company" or "the Group")
Unaudited interim results for the six months ended 31 December 2021
and cash dividend declaration
- Revenue +16%
- Gross profit +17%
- Trading profit +25%
- HEPS +30%
- Dividend +30%
- B-BBEE level 2
Introduction
The Board of Directors (Board) is very pleased to report a strong operational and financial performance,
driven mainly by improved demand in the current reporting period for its over-the-counter (OTC) and
consumer healthcare products.
The Group has achieved very healthy growth in turnover, which with some improvement in the exchange
rate, manufacturing efficiencies and cost control, has yielded an exceptional increase in trading profits
and excellent cash generation.
Dividend
The Board has declared an interim dividend of 104 cents per share for the six-month period ended
31 December 2021 out of income reserves, an increase of 30% over the comparative period and in line with
the growth in earnings.
Prospects
In December, Adcock Ingram received regulatory approval from SAHPRA for the sterile eye drops facility at
the Clayville factory. We have commenced production of validation batches of the first product we intend
to manufacture in the facility, and on a staged basis will introduce at least four additional products in
the financial year.
The Board is confident that the strength and resilience of the Company's broad and affordable portfolio of
well-known brands, can continue to withstand the macroeconomic challenges in South Africa.
The exchange rate has had a favourable impact on the Group in the period and the 2022 SEP increase of
3.5% will assist in protecting the gross margin.
Nonetheless, the Company continues to seek-out investment opportunities for non price-regulated brands
to limit the impact of the SEP environment.
Unaudited Unaudited
six-month six-month
Change period ended period ended
% 31 December 2021 31 December 2020
Revenue (R'000) 16 4 345 674 3 758 258
Gross profit (R'000) 17 1 521 652 1 298 425
Trading profit (R'000) 25 543 226 432 989
Operating profit (R'000) 33 511 584 385 813
Headline earnings per share (cents) 30 242.3 186.5
Basic earnings per share (cents) 30 242.2 186.5
Total assets (R'000) 7 560 989 7 508 322
Net asset value per share (cents) 3 096.6 2 842.8
Dividend per share (cents) 104.0 80.0
Unaudited Unaudited
six-month six-month
Change period ended period ended
% 31 December 2021 31 December 2020
Segment revenue
Consumer (R'000) 33 795 187 598 938
OTC (R'000) 26 993 915 786 150
Prescription (R'000) 5 1 572 368 1 502 632
Hospital (R'000) 13 983 891 870 323
Segment trading profit
Consumer (R'000) 59 172 934 108 782
OTC (R'000) 58 166 847 105 768
Prescription (R'000) (14) 121 878 142 249
Hospital (R'000) 6 80 565 75 798
Epi-max was moved from the Prescription segment to the Consumer segment on 1 January 2021. On a
like-for-like basis, adjusting for Epi-max, Consumer turnover and trading profit improved by 14%
and 21% respectively, and Prescription turnover and trading profit by 11% and 12% respectively.
Dividend distribution
The Board has declared an interim gross dividend out of income reserves of 104 cents per share in respect
of the six-months ended 31 December 2021. The South African dividend tax ("DT") rate is 20% and the net
dividend payable to shareholders who are not exempt from DT is 83.2 cents per share. Adcock Ingram
currently has 175 758 861 ordinary shares in issue and qualifying for ordinary dividends. The income tax
reference number is 9528/919/15/3.
The salient dates for the distribution are detailed below:
Last date to trade cum distribution Tuesday, 15 March 2022
Shares trade ex distribution Wednesday, 16 March 2022
Record date Friday, 18 March 2022
Payment date Tuesday, 22 March 2022
Share certificates may not be dematerialised or rematerialised between Wednesday, 16 March 2022 and
Friday, 18 March 2022, both dates inclusive.
N Madisa AG Hall
Chairperson Chief Executive Officer
Approved by the Board: 22 February 2022
SENS release date: 23 February 2022
Company secretary
M Phalafala
Registered office
1 New Road, Midrand, 1682
Postal address
Private Bag X69, Bryanston, 2021
Transfer secretaries
Computershare Investor Services Proprietary Limited,
Rosebank Towers, 15 Biermann Avenue, Rosebank, Johannesburg, 2196.
Private Bag X9000, Saxonwold, 2132
Auditors
PricewaterhouseCoopers Inc, 4 Lisbon Lane, Waterfall, 2090
Sponsor
Rand Merchant Bank (a division of FirstRand Bank Limited),
1 Merchant Place, corner Fredman Drive and Rivonia Road, Sandton, 2196
Bankers
Nedbank Limited, 135 Rivonia Road, Sandown, Sandton, 2146.
Rand Merchant Bank, 1 Merchant Place, corner Fredman Drive and Rivonia Road, Sandton, 2196.
Investec Bank Limited, 100 Grayston Drive, Sandton, 2146
The full announcement has been published on SENS and is available at
https://senspdf.jse.co.za/documents/2022/JSE/ISSE/AIP/AIP012022.pdf
The contents of this short-form summary announcement are the responsibility of the
Board of Directors. Any investment decision should be considered and based on the content
of the information contained in the full announcement, that will be published on the Company's
website at www.adcock.com/investors/financialreports. Copies of the full announcement are
available for inspection at the registered office of the Company and may be requested without
charge during office hours by phoning +27 11 635 0143.
Date: 23-02-2022 07:05:00
Produced by the JSE SENS Department. The SENS service is an information dissemination service administered by the JSE Limited ('JSE').
The JSE does not, whether expressly, tacitly or implicitly, represent, warrant or in any way guarantee the truth, accuracy or completeness of
the information published on SENS. The JSE, their officers, employees and agents accept no liability for (or in respect of) any direct,
indirect, incidental or consequential loss or damage of any kind or nature, howsoever arising, from the use of SENS or the use of, or reliance on,
information disseminated through SENS.